Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Modified Double-Blind, Active Controlled Study to Characterize the Safety and Immunogenicity of IVX-A12 in Adults 60 Years of Age and Older

NCT06481579 is registered in ClinicalTrials.gov with Icosavax, Inc. as lead sponsor.

NCT NCT06481579
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06481579 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Modified Double-Blind, Active Controlled Study to Characterize the Safety and Immunogenicity of IVX-A12 in Adults 60 Years of Age and Older
Lead sponsor
Icosavax, Inc.
Phase
Phase 2
Overall status
Completed
Start date
June 10, 2024
Completion date
December 19, 2024
Enrollment
143 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

healthy participants